Summary Morphological and morphometric data showing a higher number of mast cells (MCs) in the stroma of B-cell non-Hodgkin's lymphomas (B-NHL) than in benign lymphadenopathies are presented in support of the suggestion that angiogenesis during the progression of B-NHL may be partly mediated by angiogenic factors in their secretory granules.
Many data suggest that the density of mast cells (MCs) is highly correlated with the extent of both normal and pathological angiogenesis, such as that in chronic inflammatory diseases and tumours (for review see Meininger and Zetter, 1992; Norrby and Woolley, 1993) . In experimentally induced tumours too, MCs accumulate close to the tumour cells before the onset of angiogenesis (Kessler et al, 1976) , and in tumours induced in MC-deficient mice both the reduced angiogenesis and the ability to produce metastasis have been shown (Starkey et al, 1988; Dethlefsen et al, 1994) . On the other hand, angiogenesis is fundamental for tumour progression in the form of growth, invasion and metastasis (Folkman, 1995) . Microvessels promote growth because they convey nutrients and oxygen and remove catabolites, whereas endothelial cells secrete paracrine growth factors for tumour cells (Hamada et al, 1992) . They facilitate invasion because endothelial cells at their tips secrete several extracellular matrix-degrading enzymes, which allow the tumour to spread into and through the adjacent matrix (Mignatti and Rifkin, 1993) . They permit metastasis because the expanding endothelial surface offers tumour cells more opportunities to enter the circulation (Aznavoorian et al, 1993) .
We have shown that angiogenesis is more intense in the stroma of B-cell non-Hodgkin's lymphomas (B-NHLs) than that of benign lymphadenopathies, and that microvessel density increases in function with tumour progression, as defined by its increasing malignancy grades . In this study, we correlate the extent of angiogenesis with the number of MCs in benign lymphadenopathies and B-NHL.
MATERIALS AND METHODS Tissues
Representative samples of 74 B-NHL nodes and 12 benign lymphadenopathies obtained with informed consent before therapy were studied (Table 1) . B-NHLs were classified according to the Working Formulation (WF) malignancy grades (1989), entailing distinct steps of progression because of large increments in tumour cell growth rate (S-fraction) in the intermediate and high grade (Wain et al, 1987) , or with transition from the low-to the intermediate-and high-grade (Joensuu et al, 1990) . Lymphadenopathies were nine reactive and three atypical lymphoid hyperplasias. Reactive forms displayed either follicular hyperplasia (lymphadenitides, rheumatoid lymphadenopathies) or histiocyte hyperplasia (those draining carcinomas). Atypical forms displayed follicular hyperplasia.
Each sample was divided into two parts immediately after surgical removal: one part was formalin fixed and paraffin embedded for histopathology and immunohistochemistry; the second was processed for electron microscopy.
Immunohistochemistry
A three-layer biotin-avidin-peroxidase system was used, as described previously . Briefly, 8-jm sections were deparaffinized by the xylene-ethanol sequence, depleted of their endogenous peroxidase by 0.3% hydrogen peroxide/0.1% sodium azide, treated with 0.1% trypsin (Sigma Chemical, St Louis, MO, USA) and sequentially incubated with (a) murine monoclonal antibodies (MAbs) against the endothelial cell marker factor VIII (MAb M616, Dako Glostrup, Denmark) and various B cell-and T cell-specific markers for typing the lymphoma lineage and for exclusion of malignancy in atypical hyperplasias, as described previously (Vacca et al, 1994) ; (b) biotin-labelled horse anti-mouse Ig (Vector, Burlingame, CA, USA); and (c) streptavidin-peroxidase conjugate (Dako). Sections were then red-stained with a 3-amino-9-ethylcarbazole (Sigma Chemical) solution, counterstained with Gill's haematoxylin no. 2 (Polysciences, Warrington, PA, USA), and mounted in buffered glycerin. In negative controls, the MAbs were replaced by an indifferent murine monoclonal IgG1 (Vacca et al, 1994) .
Microvessel counts These were simultaneously assessed without knowledge of the final pathological diagnosis by two investigators with a doubleheaded light microscope (Leitz Dialux 20, Leitz, Wetzlar, Germany). Four-six 200x fields covering almost the whole of each of three sections (every third section within nine serial sections) per sample were examined with a 144-intersection point square reticulum (0.78 mm2) inserted in the eyepiece. Care was taken to select microvessels, i.e. capillaries and small venules, from all the stained vessels. They were identified as transversally sectioned tubes with a single layer of endothelial cells, either without or with a lumen (not exceeding 10 jm), and either without or with a thin basement membrane. Each assessment was agreed upon in turn. Microvessels showing reactivity with factor VIII are of both blood and lymphatic origin and useful markers of angiogenesis (Folkman et al, 1989) . They were counted with a planimetric point-count method (Elias and Hyde, 1983 ) with slight modifications (Vacca et al, 1993) , according to which only microvessels transversally cut occupying the reticulum intersection points were counted. As the microvessel diameter was smaller than the distance between adjacent intersection points, only one transversally sectioned microvessel could occupy a given intersection point. Microvessels transversally sectioned outside the points and those longitudinally or tangentially sectioned were omitted. Therefore, it was sufficiently certain that a given microvessel was counted only once, even in the presence of several of its section planes. The method also makes allowances for the inhomogeneous distribution of microvessels in tissues (Elias and Hyde, 1983) . Indeed, in line with other (Kittas et al, 1985) and our own observations MC counts MCs were highlighted in two sections adjacent to that stained for microvessels with a 0.5% aqueous solution of toluidine blue (Merk, Darmstadt, Germany). Cells were counted in 6-8 250x fields, covering almost the whole section, inside the square reticulum (0.25 mm2), and calculated as means ± 1 s.d. for each group of samples.
Electron microscopy Small pieces (approximately 1 mm3) of tissue were fixed in 3% gluteraldehyde in 0.1 M phosphate-buffered saline (PBS) for 3 h, washed in the same buffer for 12 h, post-fixed in 1% osmium tetroxide, dehydrated in graded ethanols and embedded in Epon 812. Ultrathin sections were cut with a diamond knife on a LKB V ultratome, stained with uranyl acetate followed by lead citrate and examined in a 9A Zeiss electron microscope. Figure 1 . The withingroup comparisons showed that both counts were always significantly correlated (Figure 2 Number of microvessels around blood or lymphatic capillaries ( Figure 3A and C) . At the ultrastructural level, MCs showed the typical features of the connective tissue MCs, with their cytoplasmic matrix filled by numerous electron-dense secretory granules ( Figure 3B ).
DISCUSSION
This paper shows that angiogenesis in benign lympadenopathies and in B-NHL, measured as microvessel counts, is highly correlated with the MC counts, and that both counts increase in step with the increase in WF malignancy grades. Both haematic and lymphatic endothelial cells of node tissues have been shown to proliferate in vitro in response to angiogenic cytokines, such as basic fibroblast growth factor (FGF-2) and vascular endothelial growth factor (VEGF) (Pepper et al, 1994) . The peritumoral inflammatory infiltrate surrounding the newly formed small blood and lymphatic vessels in the stroma of B-NHL consists of fibroblasts, MC and other leucocytes that may contribute to induction of the angiogenic response by secreting those factors (Folkman and Brem, 1992) .
MCs are strikingly associated with angiogenesis, as found in chronic inflammatory diseases, namely rheumatoid arthritis and psoriasis, and in tumours, namely haemangiomas and carcinomas (Meininger and Zetter, 1992; Norrby and Woolley, 1993; Qu et al, 1995) . In tumours, MCs are recruited and activated via several factors secreted by tumour cells: the c-kit receptor, or stem cell factor (Poole and Zetter, 1983; Norrby and Wooley, 1993) , as well as FGF2, VEGF and platelet-derived endothelial cell growth British Journal of Cancer (1998) factor (PD-ECGF), which are operative at picomolar concentrations (Gruber et al, 1995) . ' [he fact that MCs contribute to the induction of tumour angiogenesis stems from studies on MC-deficient mice, which give slow angiogenesis, and its restoration after local reconstitution of MCs (Starkey et al, 1988) . MCs also contain heparin in secretory granules. In vitro, heparin stimulates endothelial cell proliferation and migration (Thorton et al, 1983; Alessandri et al, 1984) , whereas in vivo it has been found to stimulate (Ribatti et al, 1987; Norrby and Sorbo, 1992; Norrby, 1993) , inhibit (Jakobson and Hahnenberger, 1991; Wilks et al, 1991; Norrby, 1993) or have no effect (Castellot et al, 1982; Taylor and Folkman, 1982) . However, these properties seem to be related to its molecular size and degree of sulphation. The 22-kDa and 2.4-kDa heparin fractions display stimulatory and inhibitory properties respectively (Norrby, 1993) ; N-sulphate, but not 0-sulphate groups are necessary for the release of the extracellular matrix (heparan sulphate)-bound FGF-2 as their whole replacement by acetyl or hexanoyl groups, despite the normal 0-sulphate content, abolishes the FGF-2-releasing activity (Ishai-Michaeli et al, 1992) . This activity is because heparin acts as a soluble form of the low-affinity FGF-2 receptor (Folkman and Shing, 1992) , which displaces FGF-2 in the biologically active form, thus allowing its rapid interaction with endothelial cells (Yayou et al, 1991) .
Histamine, another MC-derived factor, also stimulates angiogenesis (Sorbo et al, 1994) , and tryptase, another MC mediator, has been shown to be a potent angiogenic factor (Blair et al, 1997) . In addition, MCs produce a variety of multifunctional cytokines and growth factors, such as transforming growth factor P (Roberts et al, 1986) , interleukins 6 and 8 (Motro et al, 1990; Norrby, 1996) , granulocyte macrophage-colony stimulating factor (Bussolino et al, 1991) , tumour necrosis factor x (Beil et al, 1994) , (Qu et al, 1995) and VEGF (Grutzkan et al, 1996) , which may contribute to angiogenesis in B-NHL.
In conclusion, our data suggest that an increasing number of MCs may be recruited and activated by more malignant B-NHL cells, and that angiogenesis associated with B-NHL may be mediated by angiogenic factors contained in their secretory granules.
